The News
Product Showcase at Vaccine Conference May 7-8, 2012 PDF Print E-mail
Written by Administrator   
Thursday, 29 March 2012 10:45

Molecular Express product showcase at the 15th Annual Conference on Vaccine Research May 7-8, 2012 in Baltimore, Maryland

Molecular Express representatives will be participating at the Fifteenth Annual Conference on Vaccine Research product exhibition being held at the Hyatt Regency Inner Harbor Hotel in Baltimore, Maryland from May 7-8th.  We will be there from 5pm to 7pm on May 7th and 7:30am to 1pm on May 8th.  You are invited to visit us at our booth (109), meet our representatives and learn about our exciting product line of vaccine research tools.  For more information on the conference please visit http://www.nfid.org/.

 

Last Updated on Friday, 30 March 2012 08:16
 
AsiaTIDES Conference Appearance February 28-March 1, 2012 in Tokyo, Japan PDF Print E-mail
Written by Administrator   
Thursday, 16 February 2012 11:48

Dr. Gary Fujii, President and CEO of Molecular Express, Inc., will be presenting at the upcoming AsiaTIDES Conference in Tokyo, Japan.  He will be speaking about the VesiVax® Conjugatable Adjuvant Lipid Vesicles (CALV).

Last Updated on Thursday, 22 March 2012 09:50
 
Molecular Express announces award of STTR Phase I funding from the National Institutes of Health to develop a liposomal nicotine vaccine PDF Print E-mail
Written by Administrator   
Thursday, 16 February 2012 11:47

Nicotine is the most widely used, readily available legal psychostimulant in the world and is highly addictive.  Current nicotine addiction treatments include nicotine replacement therapies, but this approach has yielded only modest results.  Molecular Express, Inc., in collaboration with Professor Kim Janda at The Scripps Research Institute, will engineer a liposomal nicotine vaccine through which an individual’s immune system will generate antibodies to sequester the nicotine in the bloodstream. 

Last Updated on Thursday, 22 March 2012 09:49
 
Molecular Express announces award of SBIR contract from the National Institutes of Health to develop Viratrodes as a Biosensor for the Improved Diagnosis of Cancer PDF Print E-mail
Written by Administrator   
Thursday, 16 February 2012 11:46

Molecular Express will develop a highly sensitive biosensor that can detect circulating tumor cells and cancer biomarkers.  The viratrode technology, licensed from  the University of California, Irvine and developed by  Professor Gregory Weiss and Chancellor’s Professor Reginald Penner, incorporates a bioaffinity layer consisting of a “kelp forest” of filamentous phage particles, with a sensitive electronic area detector capable of detecting low nM concentrations of biomarkers.  The viratrode for this contract will be adapted with phage particles displaying multiple ligands to a particular cancer biomarker.  This project will lay the groundwork for the development of a point-of-care device capable of recognizing, capturing and quantifying tumor cells and biomarkers for prostate cancer in the circulating peripheral blood (and potentially other biofluids) of a cancer patient.

Last Updated on Monday, 19 March 2012 16:09
 
Latest finding of liposomal M2e influenza vaccine published in Vaccine June 2011 PDF Print E-mail
Written by Administrator   
Thursday, 16 February 2012 11:43

The article, “Characterization of the murine Th2 response to immunization with liposomal M2e influenza vaccine”, was published in Volume 29, Issue 27 of Vaccine.  This report highlights the results of a liposome-based vaccine with the ectodomain of the matrix 2 (M2e) channel protein as a universal influenza vaccine candidate.  This vaccine (L-M2e-HD/MPL) stimulate anti-M2e antibodies production which conferred complete protection upon passive transfer.  IL-4 and IFN-γ splenocyte secretions and CD4/CD8 depletion studies suggest a Th2 response mechanism.  For the full article, http://dx.doi.org/10.1016/j.vaccine.2011.04.040.

Last Updated on Monday, 19 March 2012 16:09
 
<< Start < Prev 1 2 Next > End >>

Page 1 of 2